Catalent (CTLT) Reports In-Line Q1 EPS, Reaffirms Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. CVS
9. SPY
10. XYZ

Go back to Catalent (CTLT) Reports In-Line Q1 EPS, Reaffirms Guidance

Catalent, Inc. Reports First Quarter Fiscal 2019 Results

November 6, 2018 7:30 AM EST

Q1'19 revenue of $551.8 million increased 1% as-reported, or 3% in constant currency, from the prior-year period. Closed the acquisition of Juniper Pharmaceuticals, a European early development Center of Excellence with dose form development and clinical manufacturing capabilities. FY'19 financial guidance reaffirmed.

SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the first... More